Efficacy of eccentric dosing with sustained-release isosorbide dinitrate in patients with angina pectoris.

Abstract

OBJECTIVE:

To assess the anti-anginal efficacy of eccentric dosing with a sustained-release formulation of isosorbide dinitrate (ISDN) administered twice daily in an eccentric fashion (08:00 and 14:00).

DESIGN:

A placebo controlled crossover study of 16 patients with chronic stable angina who received, in random order, either placebo or sustained-release ISDN 40 mg twice daily for a period of seven to 10 days. Patients were entered who had reproducible exercise test to the development of moderate angina. All anti-anginal drugs with the exception of beta-blockers were withheld during the study period. The primary end-point was the treadmill walking time to the development of moderate angina.

RESULTS:

Patients receiving active therapy showed a significant increase in treadmill walking time to moderate angina over that seen with placebo at 3 and 6 h after the morning dose and 3 and 8 h after the afternoon dose. Similar trends occurred for the time to onset of angina and the time to development of 1 mm of ST segment depression on the electrocardiogram.

CONCLUSIONS:

Eccentric dosing with sustained-release ISDN, 40 mg given 6 h apart, provided significant improvement in exercise performance for up to 14 h during sustained therapy.

• Authors: J O Parker, M G Baird
• Journal: The Canadian journal of cardiology (Can J Cardiol) Vol. 10 Issue 9 Pg. 909-12 (Nov 1994) ISSN: 0828-282X [Print] England
• PMID: 7954026 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Delayed-Action Preparations
• Isosorbide Dinitrate

Topics

• Angina Pectoris (diagnosis, drug therapy, physiopathology)
• Chronic Disease
• Cross-Over Studies
• Delayed-Action Preparations
• Double-Blind Method
• Electrocardiography
• Exercise Test
• Humans
• Isosorbide Dinitrate (administration & dosage, therapeutic use)